SLC16A1 and neoplasm: Beyond PDAC, clinical and preclinical studies in other cancers have demonstrated the efficacy of targeting SLC transporters such as SLC7A5 (LAT1) [61], SLC16A1 (MCT1) [62], and SLC6A14 [63] in suppressing tumor growth and modulating therapeutic resistance.